AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
COSTA MESA, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 trial and completed dosing the first cohort of patients diagnosed with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME).?
“We are very excited to have initiated this U.S. trial,” said Diane Tang-Liu, PhD, CEO, President & Co-Founder of AiViva Biopharma.?“AIV007 is a broad spectrum tyrosine kinase inhibitor, targeting the convergence of fibrosis, angiogenesis, and inflammation. We believe AIV007 coupled with our proprietary JEL™ technology and administered periocularly, will address the root causes of many ocular diseases.”
This Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial. Up to 24 subjects will receive a single periocular injection and will undergo monthly evaluation for up to 6 months to asses safety, tolerability, and efficacy measured by best corrected visual acuity (BCVA).
About Age-Related Macular Degeneration and Diabetic Macular Edema
Diabetic macular edema is manifested as retinal thickening and swelling caused by accumulation of intraretinal fluid usually due to blood sugar levels being consistently high.?If untreated, chronic macular edema can lead to irreversible damage of the macula and permanent vision loss.?
About AiViva Biopharma, Inc.?